Technology Networks

CytRx Corporation

11726 San Vicente Blvd.,
Suite 650,
Los Angeles,
CA 90049
United States of America
Tel: 310-826-5648
Fax: 310-826-6139

Print Email to a friend

CytRx Corporation, located in Los Angeles, California, is focused on the development and commercialization of high-value human therapeutics. Our proprietary platform technology is based on our know how in the chemistry of surface active molecules known as poloxamers and our extensive library of proprietary poloxamer compounds. We believe the therapeutic utility of these compounds is based on their ability to modify the most universal property of living systems: the interaction between cells and molecules with water.

Further Information: http://www.cytrx.com


Related news from our archive

CytRx’s Arimoclomol to be Administered in a Phase 2/Phase 3 Adaptive Clinical Trial
The FDA funded clinical trial has commenced to study molecular chaperone regulator drug candidate in a subset of patients with familial ALS.

CytRx Unveils Clinical Development Plan for Pipeline Assets
Company pursues partnerships to advance the clinical development of its oncology drug candidates and its clinical molecular chaperone portfolio.

CytRx Reports Favorable Safety and Tolerability Results from High Dose, 28-Day Clinical Trial with Arimoclomol
Results support four-fold higher arimoclomol dose for planned Phase IIb efficacy trial for ALS.

CytRx Contributes $15 Million net to Majority-Owned RNAi Subsidiary RXi Pharmaceuticals
The contribution will satisfy RXi’s funding requirements under its agreements with the UMMS, and will increase CytRx’s ownership in RXi to nearly 90%.

CytRx’s Arimoclomol to be Administered in a Phase 2/Phase 3 Adaptive Clinical Trial
The FDA funded clinical trial has commenced to study molecular chaperone regulator drug candidate in a subset of patients with familial ALS.

CytRx Unveils Clinical Development Plan for Pipeline Assets
Company pursues partnerships to advance the clinical development of its oncology drug candidates and its clinical molecular chaperone portfolio.

CytRx Reports Favorable Safety and Tolerability Results from High Dose, 28-Day Clinical Trial with Arimoclomol
Results support four-fold higher arimoclomol dose for planned Phase IIb efficacy trial for ALS.

CytRx Contributes $15 Million net to Majority-Owned RNAi Subsidiary RXi Pharmaceuticals
The contribution will satisfy RXi’s funding requirements under its agreements with the UMMS, and will increase CytRx’s ownership in RXi to nearly 90%.